The Precision Oncology Exchange with TJ is a new webinar series that serves as an interactive Q&A forum designed to explore recent oncology research and real-world clinical applications.
Hosted by Dr Thomas “TJ” Slavin, each short, informal session explores clinical and real-world applications of minimal residual disease (MRD) testing—how it’s being used in practice today and what the latest data reveal.
We are excited to announce the launch of a pilot program between Haystack MRD® by Quest Diagnostics® and OncoEMR! Select providers now have access to Haystack MRD via OncoEMR MPI capability – meaning that you may be able to order
New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has officially approved Haystack MRD® for use in identifying residual or recurring disease in patients with solid tumor cancers.
Para solicitar ayuda financiera, complete la solicitud y firme la autocertificación.
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
